Drugs / COTI2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02433626 | Dec 2015 → Dec 2019 | cervical cancer, colorectal cancer, endometrial cancer, fallopian tube cancer +5 | Critical Outcome Technologies Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COTI2 | “COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week.” NCT02433626 ↗1“Drug: COTI2” NCT02433626 ↗ |
| Modality | Small molecule | “COTI-2 is a third generation thiosemicarbazone.” NCT02433626 ↗ |
| Route | Oral | “COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week.” NCT02433626 ↗ |